Research Article ISSN: 2771-9073

Insights in Blood Disorders

Idiosyncratic Drug-Induced Agranulocytosis: Entering the 21st Century Leveraging Risk Clusters, Big Data, Artificial Intelligence, and Technological Innovations for Enhanced Patient Care

Emmanuel Andrès[1,2*], Xavier Jannot[1,2], Thierry Lavigne[3], Frédéric Maloisel[4], Amir El Hassani Hajjam[5], Maria Belén Alonso Ortiz[6], Manuel Méndez Bailón[7] and Lorenzo-Villalba N[1,2]

[1]*Service de Médecine Interne, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, France.*

[2]*Centre de compétence des cytopénies du Bas–Rhin, Hôpitaux Universitaires de Strasbourg, France.*

[3]*Service d'Hygiène Hospitalière et Pôle de Santé Publique, Hôpital Civil, Hôpitaux Universitaires de Strasbourg.*

[4]*Service d'Hématologie, Clinique Saint-Anne, Strasbourg, France.*

[5]*Laboratoire de Nanomédecine imagerie et thérapeutique, Université de Technologie de Belfort Montbéliard.*

[6]*Servicio de Medicina Interna. Hospital Universitario de Gran Canaria Dr Negrin, Spain.*

[7]*Servicio de Medicina Interna. Hospital Universitario Clínico San Carlos, Spain.*

***Correspondence:**

Emmanuel Andrès, Service de Médecine Interne, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, France.

Received: 10 June 2025; **Accepted:** 08 July 2025; **Published:** 17 July 2025

Citation: Emmanuel Andrès, Xavier Jannot, Thierry Lavigne, et al. Idiosyncratic Drug-Induced Agranulocytosis: Entering the 21st Century Leveraging Risk Clusters, Big Data, Artificial Intelligence, and Technological Innovations for Enhanced Patient Care. Insights Blood Disord. 2025; 4(1): 1-9.

ABSTRACT

Idiosyncratic drug-induced agranulocytosis is a rare but potentially fatal adverse drug reaction characterized by a sudden and profound drop in neutrophil count, predisposing patients to severe infections. Despite its low incidence, idiosyncratic drug-induced agranulocytosis remains a significant clinical challenge due to its unpredictable onset and the wide array of medications implicated in its occurrence. Traditional management relies on early recognition and immediate drug withdrawal, but preventive strategies have historically been limited. Recent advances in pharmacogenomics have improved our understanding of individual susceptibility, with certain HLA alleles and genetic polymorphisms emerging as key risk factors. The identification of risk clusters—including genetic, demographic, and clinical features—supports more tailored prevention. Big data analytics and artificial intelligence (AI) now offer promising tools for predictive modeling and real-time pharmacovigilance signal detection. Technological innovations such as telemedicine, wearable sensors, and home-based blood cell monitoring enable earlier detection and intervention, especially in high-risk patients. Therapeutic patient education (TPE) plays a crucial role in increasing awareness, promoting adherence to monitoring protocols, and empowering patients in self-management. This review highlights the convergence of scientific, clinical, and technological progress that supports a shift toward a more proactive, personalized, and preventive approach to idiosyncratic drug-induced agranulocytosis management in modern internal medicine.

Keywords
Drug-induced agranulocytosis, Risk clusters, Big data, Artificial intelligence, Telemedicine, Connected sensors, Therapeutic patient education, Prevention, Prediction.

Introduction
Idiosyncratic drug-induced agranulocytosis (IDIA) is a rare but potentially life-threatening adverse drug reaction characterized by a severe reduction in neutrophil count, often leading to serious infections and, in some cases, mortality. The condition poses a significant clinical challenge due to its unpredictable onset, the wide range of medications that can be implicated, and the absence of clear early warning signs in many cases. While certain drugs—such as antithyroid agents, clozapine, sulfonamides, and some antibiotics—have a higher documented association with IDIA, the idiosyncratic nature of the reaction implies a multifactorial etiology, involving a complex interaction of genetic predisposition, immune system responses, co-existing medical conditions, and drug-specific factors [1,2].

Despite its rarity, the high morbidity and potential for rapid clinical deterioration make IDIA a condition of critical concern in internal medicine. The lack of reliable predictive markers and the delayed onset of symptoms often hinder timely diagnosis, and once the agranulocytosis becomes clinically apparent, immediate discontinuation of the offending drug and urgent supportive care are required [3,4].

This review seeks to provide a comprehensive overview of current knowledge and emerging perspectives on IDIA. It highlights the advancements in pharmacogenomics, big data analytics, artificial intelligence (AI), and telemedicine that are transforming our approach to this condition. Special attention is given to strategies aimed at improving risk stratification, early detection, and patient monitoring, with the ultimate goal of moving toward a more proactive and personalized approach to IDIA prevention and management [5,6].

Idiosyncratic Drug-Induced Agranulocytosis
Idiosyncratic drug-induced cytopenias result from decreases in the number of blood cells such as red blood cells (anemia), neutrophils (neutropenia) or platelets (thrombocytopenia), or even several types of hematological cells (thrombotic microangiopathy), resulting from unpredictable reactions to drugs, unrelated to the dose administered or the known pharmacological properties of the drug (Table 1).

Neutropenia is a condition characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting bacterial and fungal infections. It is classified by severity: mild (1000–1500 cells/µL or 1–1.5 x 10^9/L), moderate (500–1000 cells/µL or 0.5–1 x 10^9/L), and severe (<500 cells/µL or <0.5 x 10^9/L), with infection risk increasing as counts decrease [7]. Agranulocytosis is a severe and often sudden form of neutropenia, typically defined by a neutrophil count below 500 cells/µL, and in many cases below 100 (0.1 x 10^9/L), leading to a critically compromised immune system [3].

IDIA refers to a rare (6-10 cases per million of habitants), severe drop in neutrophil count caused by an adverse drug reaction in certain individuals, where the reaction occurs due to an individual's unique genetic makeup, immune system, or other unknown factors [1,2].

Unlike general neutropenia, agranulocytosis often results from drug-induced bone marrow suppression and carries a high risk of life-threatening infections. Prompt recognition and management are crucial to prevent serious complications. These reactions are rare but can be serious. A mortality between 5 and 20% for severe neutropenia and other agranulocytosis has been reported [8]. In this context, it is essential to recognize these cytopenias as soon as possible, in order to discontinue the offending drug and institute appropriate treatment [9].

Table 1: Definition and pathophysiology of idiosyncratic drug-induced cytopenias [4-9].

Aspect	Description
Definition	Reduction in the number of blood cells (red blood cells, neutrophils or platelets) due to an unpredictable reaction to a drug, unrelated to the dose or pharmacological properties of the drug
Physiopathology	The exact mechanisms are often poorly understood, but may include: Immunological reactions: The drug or its metabolites may modify cellular antigens, resulting in an immune response against blood cells Direct toxicity: some drugs can have a direct toxic effect on hematopoietic cells or bone marrow Genetic predisposition: individual genetic variations may make some people more susceptible to developing cytopenias in response to certain drugs

IDIA can be triggered by a wide and diverse range of medications, highlighting the idiosyncratic nature of this adverse drug reaction. Historically, well-established culprits include certain antimicrobials (e.g., trimethoprim-sulfamethoxazole, some cephalosporins), non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., phenylbutazone, less commonly with newer NSAIDs), antithyroid drugs (e.g., methimazole, propylthiouracil), and the antipsychotic clozapine, which carries a particularly high risk and necessitates mandatory monitoring programs in many countries [10,11]. Other frequently implicated drug classes encompass anticonvulsants (e.g., carbamazepine), antiarrhythmics (e.g., procainamide), and certain chemotherapeutic agents (though these often cause predictable, dose-dependent myelosuppression rather than idiopathic agranulocytosis) [12,13]. Furthermore, as highlighted earlier, newer therapeutic modalities such as specific biologics (e.g., certain monoclonal antibodies) and, albeit rarely, even advanced therapies like gene therapy, cell-based therapies, and CAR T-cell therapy have been implicated in isolated cases [14,15]. The list of potentially offending drugs continues to evolve, underscoring the importance of meticulous medication

history taking and ongoing pharmacovigilance efforts to identify novel associations and understand the relative risk conferred by different agents [16,17].

Understanding Risk: The Concept of Risk Clusters in Idiosyncratic Drug-Induced Agranulocytosis

The traditional approach to drug-induced agranulocytosis has primarily focused on individual drug associations. However, this approach has limitations because the susceptibility to this condition is likely multifactorial. Recognizing this complexity requires the identification of "risk clusters"—combinations of patient characteristics, genetic predispositions, co-morbidities, and medication profiles that, when present together, significantly increase the risk of developing IDIA.

These risk clusters include several key factors:

- **Genetic Predisposition**: Specific HLA alleles and polymorphisms in genes involved in drug metabolism and immune regulation have been increasingly identified as contributing factors to the development of IDIA [18,19]. Variations in genes that influence how the body processes drugs, as well as those involved in the regulation of immune responses, may make certain individuals more susceptible to adverse reactions. Genetic testing could help identify high-risk patients who are more likely to develop IDIA when exposed to certain medications.
- **Age and Sex**: Studies have shown that older individuals and females are more likely to experience IDIA with certain medications [20,21]. This could be due to several factors, including age-related changes in drug metabolism and immune system function, as well as hormonal differences that affect immune responses. Older individuals might have a slower rate of drug elimination, leading to higher drug concentrations in the body, while females may have a different immune response that makes them more prone to adverse reactions.
- **Co-morbidities**: Underlying autoimmune diseases, infections, and hepatic or renal impairment can influence the risk of developing IDIA [22]. For example, autoimmune diseases may already cause immune dysregulation, making the body more prone to react to medications. Infections can also alter the immune system, increasing the likelihood of adverse drug reactions. Additionally, hepatic or renal impairment can affect drug metabolism and clearance, leading to higher systemic drug levels and an increased risk of immune-mediated reactions.
- **Polypharmacy and Specific Drug Combinations**: The use of multiple medications, or polypharmacy, increases the likelihood of drug interactions that can amplify or reduce the effects of specific drugs on the hematopoietic system [23,24]. Some drug combinations may have synergistic effects, heightening the risk of agranulocytosis, while others may have antagonistic effects, making it more challenging to predict the outcome. The impact of polypharmacy on drug-induced agranulocytosis needs further investigation to better understand which combinations are particularly dangerous.
- **Previous Adverse Drug Reaction History**: Individuals with a history of other idiosyncratic adverse drug reactions, particularly those involving immune-mediated mechanisms, may be at higher risk of developing IDIA. The body's immune system may have already been sensitized to certain medications, which can lead to an exaggerated response upon subsequent exposure to a similar drug or drug class [25].

Identifying these risk clusters through comprehensive data analysis is essential for improving the prediction and prevention of IDIA (Table 2) [18-25]. By understanding how different factors interact to elevate the risk of drug-induced agranulocytosis, clinicians can develop more targeted preventive and monitoring strategies. This may include personalized treatment plans based on a patient's genetic profile, medical history, and current medications, as well as more vigilant monitoring of high-risk patients. Ultimately, better identification of risk clusters will lead to improved patient outcomes and reduced incidence of this potentially fatal adverse drug reaction.

Table 2: Risk clusters for idiosyncratic drug-induced-agranulocytosis (IDIA) [18-25].

Risk Factor	Description	Impact on Risk of IDIA
Genetic Predisposition	Specific HLA alleles and polymorphisms in genes involved in drug metabolism and immune regulation Genetic testing could help identify individuals at high risk	Genetic variations affect how the body processes drugs and responds to them, increasing susceptibility to IDIA
Age and Sex	Older individuals and females are more likely to develop IDIA Age-related changes in metabolism and immune function, and hormonal differences, contribute to this increased risk	Older patients may have slower drug metabolism, while hormonal differences in females could influence immune responses
Co-morbidities	Autoimmune diseases, infections, and hepatic/renal impairment can increase the risk These conditions may influence immune regulation and drug metabolism	Co-existing diseases may exacerbate immune responses, alter drug metabolism, and make the body more prone to IDIA
Polypharmacy and Specific Drug Combinations	The use of multiple medications increases the likelihood of interactions, which can either heighten or reduce the risk of agranulocytosis Some combinations may have synergistic effects	Drug-drug interactions could amplify or alter the impact on the hematopoietic system, increasing the likelihood of IDIA
Previous Adverse Drug Reaction History	Individuals with a history of immune-mediated adverse drug reactions are at a higher risk for developing IDIA due to immune system sensitization	A prior sensitization to medications may lead to an exaggerated immune response, elevating the risk of future ADRs

The Power of Big Data and Artificial Intelligence in Idiosyncratic Drug-Induced Agranulocytosis Research

The vast amounts of data generated from sources such as electronic health records (EHRs), pharmacovigilance databases, genomic studies, and even social media present unprecedented opportunities to understand the complexities of drug-induced agranulocytosis. The application of big data analytics combined with AI algorithms can significantly enhance our ability to predict, detect, and manage

IDIA risk in patients. These technologies provide powerful tools to uncover insights that were previously difficult to identify through traditional methods.

Key opportunities provided by big data analytics and AI include improving risk identification, developing predictive models, enhancing pharmacovigilance, and personalizing patient care.

- **Identify Novel Risk Factors and Drug Associations**: Machine-learning techniques can process large and complex datasets to identify new patterns that may not be immediately apparent through conventional analysis. By analyzing extensive EHRs, pharmacovigilance reports, and genomic data, AI can uncover novel risk factors and drug-drug interactions that may elevate the likelihood of developing IDIA, particularly within specific patient subgroups [26,27]. For example, AI can identify combinations of medications or genetic variants that predispose certain individuals to agranulocytosis, leading to more accurate risk identification.
- **Develop Predictive Models**: AI can be trained on historical data to develop predictive models that assess an individual's probability of developing IDIA based on their risk cluster profile. These models can factor in genetic predisposition, age, sex, co-morbidities, and current medications. By evaluating these factors, AI could help predict how likely a patient is to experience an IDIA episode before they begin treatment with a medication known to be implicated in agranulocytosis [27,28]. Predictive models can inform clinical decisions, allowing healthcare providers to make more personalized, evidence-based prescribing choices and to monitor high-risk patients more proactively.
- **Improve Signal Detection in Pharmacovigilance**: AI-powered tools can improve the detection of signals in pharmacovigilance by analyzing spontaneous adverse drug reaction reports from a variety of sources, including clinical practice, patient registries, and social media platforms. By efficiently processing and identifying subtle patterns in this data, AI can help spot potential IDIA signals earlier than traditional methods [29,30]. This early detection allows for quicker regulatory responses, such as issuing warnings or conducting further investigations into drugs that may pose a risk of agranulocytosis. This can lead to more timely interventions and reduced adverse outcomes in the population.
- **Personalize Risk Assessment**: One of the most significant benefits of AI is its ability to integrate diverse data sources to create a personalized risk assessment for individual patients. By considering factors like genetic markers, medical history, medication profile, and even social determinants of health, AI can provide a much more nuanced and individualized understanding of IDIA risk [31,32]. This personalized approach enables healthcare providers to assess the potential risk for each patient before prescribing a medication that may carry a risk for agranulocytosis, ensuring better-informed decision-making and reducing the likelihood of harmful outcomes.

The integration of big data analytics and AI into healthcare, particularly in the context of IDIA, offers significant promise for improving drug safety and patient outcomes [33]. By identifying novel risk factors, developing predictive models, enhancing pharmacovigilance, and personalizing risk assessments, AI can help healthcare providers better understand and manage the complexities of IDIA (Table 3). As these technologies continue to evolve, they hold the potential to transform how we predict, detect, and prevent this serious adverse drug reaction, ultimately leading to safer and more effective treatments for patients.

Table 3: Key opportunities provided by big data analytics and artificial intelligence (AI) in the context of idiosyncratic drug-induced agranulocytosis (IDIA) [26-33].

Opportunity	Description	Impact on IDIA Management
Identify Novel Risk Factors and Drug Associations	Machine-learning algorithms can process vast datasets from electronic health records, pharmacovigilance databases, and genomic studies to uncover hidden patterns, such as drug-drug interactions and genetic variants	AI can reveal new risk factors and drug associations, allowing for more accurate identification of at-risk patient groups
Develop Predictive Models	AI models can be trained on historical data to predict an individual's likelihood of developing IDIA based on their risk cluster profile, such as genetic predisposition and co-morbidities	Predictive models can help foresee which patients are most likely to develop IDIA, enabling proactive risk management
Improve Signal Detection in Pharmaco-vigilance	AI-powered tools can analyze adverse drug reaction reports from diverse sources, including clinical practice, patient registries, and social media, to detect subtle patterns and signals faster	Early detection of IDIA signals leads to quicker regulatory responses, reducing the time to intervention and preventing harm
Personalize Risk Assessment	AI can integrate data from various sources, including genetic markers, medication history, and social determinants of health, to create a personalized IDIA risk profile for each patient	Personalized risk assessments allow healthcare providers to tailor treatment and monitoring plans based on individual patient risks

Innovations in Biological Understanding

Recent advancements in biology are providing deeper insights into the complex mechanisms underlying drug-induced agranulocytosis. These innovations are essential for improving prevention, diagnosis, and treatment strategies:

- **Pharmacogenomics**: Ongoing research into genetic markers associated with susceptibility to IDIA is refining our understanding of individual risk profiles [34,35]. As this field progresses, it may lead to pre-prescription genetic testing for patients taking medications known to carry a high risk of agranulocytosis, ensuring more personalized and safer prescribing practices.
- **Immunopathogenesis**: Investigating the immune mechanisms involved in IDIA, such as the formation of drug-dependent antibodies and the activation of cytotoxic T cells against neutrophils, is critical for developing targeted therapies. By understanding how the immune system responds to certain

drugs, researchers can design interventions that block or modulate these harmful immune responses, potentially reducing the incidence and severity of agranulocytosis [35,36].

- **Neutrophil Biology**: Recent breakthroughs in understanding the development, survival, and clearance mechanisms of neutrophils—the white blood cells primarily affected by agranulocytosis—are opening up new avenues for intervention [37,38]. These insights may lead to novel therapeutic targets aimed at mitigating the severity and duration of agranulocytosis, enhancing the body's ability to recover from neutrophil depletion.
- **Biomarkers**: The identification of early biomarkers that precede the onset of agranulocytosis would be invaluable for proactive monitoring and timely intervention. Ongoing research is focused on identifying such biomarkers in peripheral blood or bone marrow, which could help healthcare providers detect early warning signs of agranulocytosis before the condition becomes severe, allowing for earlier treatment and improved patient outcomes [39,40].

These biological innovations are crucial for advancing our understanding of IDIA and paving the way for more effective strategies in managing and preventing this serious adverse drug reaction [41].

Integrating Telemedicine and Connected Sensors for Enhanced Monitoring

Telemedicine and connected sensors represent promising innovations for enhancing patient monitoring, particularly during the early detection phase of drug-induced agranulocytosis. These tools can enable more proactive, personalized care by facilitating real-time health tracking and faster response to warning signs.

- **Remote Symptom Monitoring**: Telehealth platforms allow patients to regularly report symptoms from home, such as fever, fatigue, or sore throat—early signs that may indicate infection, a critical and potentially life-threatening complication of agranulocytosis [42,43]. This continuous symptom tracking supports earlier recognition of concerning developments and enables clinicians to respond more quickly.
- **Wearable Sensors**: Devices capable of continuously monitoring vital signs—such as body temperature, heart rate, and possibly oxygen saturation—offer an added layer of protection for patients at risk. Abnormal readings can trigger automated alerts to healthcare providers, prompting further evaluation [44,45]. These early warnings may allow for swift intervention before complications progress, potentially improving outcomes and reducing the need for hospitalization.
- **Home-Based Blood Cell Counts**: Emerging point-of-care testing (POCT) technologies that allow for home-based white blood cell (WBC) monitoring are particularly valuable in the context of IDIA. These devices are being designed to be user-friendly, affordable, and reliable, enabling high-risk individuals to check their blood counts more frequently without visiting a clinical laboratory. This is especially beneficial for patients who have recently started medications known to be associated with IDIA or who belong to identified risk clusters [46,47]. Early detection of a declining neutrophil count at home could drastically reduce the time to diagnosis and treatment, ultimately preventing severe complications.

In summary, the integration of telemedicine and connected health technologies into routine patient care can significantly strengthen the early monitoring of IDIA [48,49]. These innovations support a shift toward patient-centered care, enabling earlier diagnosis, timely treatment, and potentially better clinical outcomes for individuals at risk of this serious adverse drug reaction (Table 4).

Table 4: Role of telemedicine and connected sensors in enhancing the monitoring of drug-induced agranulocytosis (DIA) [42-49].

Innovation	Functionality	Impact on DIA Monitoring
Remote Symptom Monitoring	Patients use telehealth platforms to report early symptoms (e.g., fever, sore throat, fatigue) from home	Enables earlier recognition of potential infections and faster clinical response
Wearable Sensors	Continuous tracking of vital signs such as temperature, heart rate, and possibly oxygen saturation. Alerts can be sent to providers when abnormalities are detected	Facilitates real-time monitoring and allows rapid intervention before complications worsen
Home-Based Blood Cell Counts	Point-of-care testing (POCT) devices enable patients to check white blood cell counts at home, particularly neutrophils	Supports early detection of neutropenia, reduces diagnostic delay, and prevents severe outcomes in high-risk patients

The Crucial Role of Therapeutic Patient Education

Therapeutic patient education (TPE) plays a crucial role in mitigating the risks associated with drug-induced agranulocytosis. By equipping patients with knowledge and self-management tools, TPE not only promotes safer medication use but also enhances early detection and timely intervention, both of which are essential in preventing severe complications.

- **Medication Awareness**: One of the foundational goals of TPE is to ensure that patients are fully informed about the medications they are prescribed, particularly those associated with a known risk of IDIA [50,51]. This includes educating them on the potential side effects—especially the risk of agranulocytosis—and emphasizing the importance of reporting any unusual or early symptoms, such as fever, sore throat, or mouth ulcers, as these could indicate the onset of neutropenia or infection.
- **Early Symptom Recognition**: TPE empowers patients to recognize the early clinical signs of agranulocytosis. By understanding what symptoms to look out for and the seriousness of a delayed response, patients are more likely to seek immediate medical attention when warning signs appear. This can lead to earlier diagnosis and a better chance of recovery [52,53].
- **Adherence to Monitoring Protocols**: For patients on medications known to carry a risk of IDIA, adherence to routine blood monitoring is critical. TPE can improve

compliance with scheduled white blood cell (WBC) counts and follow-up appointments by helping patients understand the purpose of these tests and the potential consequences of missing them [54,55].

- **Self-Management Strategies**: TPE also supports preventive behavior. Teaching patients effective infection prevention techniques, such as maintaining proper hand hygiene, avoiding crowded places during neutropenic episodes, and recognizing signs of infection, can help reduce the risk of complications associated with low neutrophil counts [56].

Importantly, tailored TPE programs—especially those delivered through digital platforms and mobile applications—can enhance patient engagement and long-term knowledge retention. These tools offer flexible, accessible, and interactive learning experiences that can be customized to each patient's literacy level, risk profile, and personal preferences [57,58]. Features like symptom trackers, medication reminders, educational videos, and real-time chat with healthcare providers can significantly improve patient involvement in their own care.

In summary, TPE is a cornerstone of preventive care for IDIA [59]. By fostering patient awareness, early symptom recognition, adherence to monitoring, and proactive health behavior, therapeutic education enhances safety and outcomes for individuals at risk of this serious adverse drug reaction.

Prevention and Prediction: Towards a Proactive Approach

The ultimate goal in managing drug-induced agranulocytosis is its prevention. Achieving this requires a comprehensive, multi-pronged strategy that integrates clinical vigilance, technological innovation, and patient and public engagement. The following key components are essential to a preventive approach:

- **Evidence-Based Prescribing**: Clinicians must evaluate the risk-benefit profile of medications, especially those known to be associated with IDIA [60,61]. In patients identified as high risk—based on genetic, clinical, or pharmacological factors—safer alternatives should be prioritized whenever available. This careful selection of therapy is a crucial first step in reducing preventable cases of agranulocytosis.
- **Targeted Monitoring Strategies**: Effective prevention also relies on risk-stratified monitoring protocols, tailored to individual patient risk cluster profiles. For high-risk patients, this may include more frequent blood count assessments, supported by innovations such as telemedicine and connected sensors [62,63]. These technologies enable remote tracking of symptoms and vital signs, allowing for earlier detection of neutropenia and rapid clinical response.
- **Pre-prescription Risk Assessment**: The use of AI-powered predictive models offers a transformative tool for risk prevention. By analyzing genetic data, comorbidities, medication history, and other relevant factors, these models can estimate a patient's likelihood of developing IDIA before initiating therapy [64,65]. This facilitates personalized prescribing decisions and customized monitoring plans, reducing the risk of adverse outcomes.
- **Pharmacovigilance Enhancement**: Strengthening pharmacovigilance systems is essential for real-time detection and evaluation of IDIA cases. Integrating big data analytics and AI into these systems can improve signal detection, enabling earlier identification of emerging drug safety concerns and more timely regulatory interventions [66,67]. Enhanced reporting and analysis mechanisms also contribute to a more accurate understanding of IDIA incidence and risk factors.
- **Public Awareness Campaigns**: Educating both healthcare professionals and the public is critical to prevention efforts. Campaigns should focus on increasing awareness of IDIA risks, promoting early symptom recognition, and emphasizing the importance of prompt reporting. Ensuring that clinicians and patients are informed can lead to faster diagnosis, discontinuation of the offending drug, and initiation of appropriate treatment [68].

In conclusion, preventing IDIA requires a coordinated approach that spans clinical decision-making, patient engagement, technological support, and public health communication. By aligning these efforts, healthcare systems can significantly reduce the incidence and impact of this serious adverse drug reaction, ultimately improving safety and outcomes for patients [69-70].

Conclusion

IDIA remains a significant clinical challenge due to its unpredictable nature, potential severity, and wide range of implicated medications. However, the convergence of advancements across multiple disciplines offers a transformative opportunity to shift from reactive to proactive care.

Progress in the identification of risk clusters—through the analysis of genetic predispositions, patient characteristics, comorbidities, and medication profiles—has laid the groundwork for more targeted prevention strategies. At the same time, the integration of big data analytics and AI is enabling the development of sophisticated predictive models that can estimate an individual's risk of IDIA before exposure to high-risk drugs. These models offer the potential for personalized prescribing and monitoring protocols, reducing the likelihood of adverse outcomes.

Innovations in biological research, including advances in pharmacogenomics, neutrophil biology, and immunopathogenesis, are deepening our understanding of the mechanisms underlying IDIA. These insights may lead to the development of targeted therapies and biomarkers for early detection. Meanwhile, connected health technologies—such as wearable sensors, telemedicine platforms, and home-based blood monitoring devices—are revolutionizing how patients at risk are monitored, enabling earlier intervention and reducing the burden on healthcare systems.

By embracing this multidisciplinary toolkit, we can move toward

a more personalized, predictive, and preventative approach to managing IDIA, with the ultimate goal of improving patient safety and clinical outcomes in internal medicine. However, further research is critical to fully realize these advancements. This includes the validation of risk clusters in diverse populations, the refinement and clinical validation of AI-driven predictive tools, and the assessment of the real-world utility of connected monitoring technologies. Only through rigorous study and careful implementation can we translate scientific and technological progress into tangible benefits for patients at risk of this rare but serious adverse drug reaction.

References

1. Andrès E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia & agranulocytosis. QJM. 2017; 110: 299-305.
2. Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol. 2015; 11: 243-257.
3. Shad MU. Pharmacogenomic screening for agranulocytosis and efficacy with clozapine. J Transl Genet Genom. 2023; 7: 141-165.
4. Dsouza VS, Leyens L, Kurian JR, et al. Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients. Research Social Administrative Pharmacy. 2025; 21: 453-462.
5. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007: 47: 513-539.
6. Andrès E, El Hassani Hajjam A, Maloisel F, et al. Artificial Intelligence (AI) and Drug-Induced and Idiosyncratic Cytopenia: The Role of AI in Prevention, Prediction, and Patient Participation. Hematol Rep. 2025; 17: 24.
7. Liang L, Hu J, Sun G, et al. Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources. Drug Saf. 2022; 45: 511-519.
8. Rattay B, Benndorf RA. Drug-Induced Idiosyncratic Agranulocytosis - Infrequent but Dangerous. Front Pharmacol. 2021; 12: 727717.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245.
10. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007; 47: 513-539.
11. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020; 99: 2477-2482.
12. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008: 15: 15-21.
13. Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017; 8: 187-193.
14. Andrès E, Villalba NL, Zulfiqar AA, et al. State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies. J Clin Med. 2019; 8: 1351.
15. Lin H, Cheng J, Mu W, et al. Advances in Universal CAR-T Cell Therapy. Front Immunol. 2021; 6: 744823.
16. Duwez M, Szymanski G, Carre M, et al. Idiosyncratic drug-induced agranulocytosis: 7 year-analysis in a French university hospital. Ann Pharm Fr. 2020; 78: 230-241.
17. Aasim Shamim M, Aaqib Shamim M, Arora P, et al. Artificial intelligence and big data for pharmacovigilance and patient safety. J Med Surg Public Health. 2024; 3: 100139.
18. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007; 146: 657-665.
19. Chen WT, Chi CC. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies. Br J Clin Pharmacol. 2019; 85: 1878-1887.
20. Ibáñez L, Vidal X, Ballarín E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005; 165: 869-874.
21. Lorenzo-Villalba N, Alonso-Ortiz MB, Maouche Y, et al. Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients. J Clin Med. 2020; 9: 1808.
22. Vial T, Pofilet C, Pham E, et al. Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years. Therapie. 1996; 51: 508-515.
23. Sommer J, Viviani R, Wozniak J, et al. Dealing with adverse drug reactions in the context of polypharmacy using regression models. Sci Rep. 2024; 14: 27355.
24. Zopf Y, Rabe C, Neubert A, et al. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals Drug Saf. 2008; 31: 789-798.
25. Curtis BR. Drug-induced immune neutropenia/ agranulocytosis. Immunohematology. 2014; 30: 95-101.
26. Huang X, Xie X, Huang S, et al. Predicting non-chemotherapy drug-induced agranulocytosis toxicity through ensemble machine learning approaches. Front Pharmacol. 2024; 14: 1431941.
27. Chen WT, Chi CC. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies. Br J Clin Pharmacol. 2019; 85: 1878-1887.
28. Iverson S, Zahid N, Uetrecht JP. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem Biol Interact. 2002; 142: 175-199.
29. Hughes JH, Tong DMH, Burns V, et al. Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning model. CPT Pharmacometrics Syst Pharmacol. 2023; 12: 1764-1776.

30. Gallardo-Pizarro A, Peyrony O, Chumbita M, et al. Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning. Expert Rev Anti Infect Ther. 2024; 22: 179-187.
31. Choo H, Yoo SY, Moon S, et al. Deep-learning-based personalized prediction of absolute neutrophil count recovery and comparison with clinicians for validation. J Biomed Inform. 2023; 137: 104268.
32. Sheehy J, Gallanagh M, Sullivan C, et al. Clinical prediction models for febrile neutropenia and its outcomes: a systematic review. Support Care Cancer. 2025; 33: 537.
33. Salas M, Petracek J, Yalamanchili P, et al. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. Pharmaceut Med. 2022; 36: 295-306.
34. Islam F, Men X, Yoshida K, et al. Pharmacogenetics-Guided Advances in Antipsychotic Treatment. Clin Pharmacol Ther. 2021; 110: 582-588.
35. De With SAJ, Pulit SL, Staal WG, et al. More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J. 2017: 17: 304-311.
36. Arndt PA, Leger RM. Introduction to immunohematology special edition on drug-induced immune cytopenias. Immunohematology. 2014; 30: 43.
37. Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017; 1: 187-193.
38. Bhatt V, Saleem A. Drug-induced neutropenia--pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004; 34: 131-137.
39. Matzner Y. Neutrophil pathophysiology. Semin Hematol. 1997; 34: 265-266.
40. Sun C, Zhao L, Yuan Y, et al. Detection of drug safety signal of drug-induced neutropenia and agranulocytosis in all-aged patients using electronic medical records. Pharmacoepidemiol Drug Saf. 2023; 32: 416-425.
41. Medrano-Casique N, Tong HY, Borobia AM, et al. Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. Pediatr Hematol Oncol. 2016; 33: 441-456.
42. Nystazaki M, Alevizopoulos G. Clozapine treatment: Ensuring ongoing monitoring during the COVID-19 pandemic. Psychiatriki. 2021; 32: 165-166.
43. Coppo P, Corre E, Rondeau E, et al. Centre de référence des microangiopathies thrombotiques. Telemedicine in thrombotic microangiopathies: A way forward in rare diseases requiring emergency care. Rev Med Interne. 2016; 37: 514-520.
44. Steig A, Miller F, Shreim S, et al. Remote management of anaemia in patients with end-stage kidney disease using a wearable, non-invasive sensor. Clin Kidney J. 2024; 18: 375.
45. Issom DZ, Henriksen A, Woldaregay AZ, et al. Factors Influencing Motivation and Engagement in Mobile Health Among Patients With Sickle Cell Disease in Low-Prevalence, High-Income Countries: Qualitative Exploration of Patient Requirements. JMIR Hum Factors. 2020.
46. Gould Rothberg BE, Quest TE, Yeung SJ, et al. Oncologic emergencies and urgencies: A comprehensive review. CA Cancer J Clin. 2022; 72: 570-593.
47. Haeusler GM, Gaynor L, Babl FE, et al. Home-based care of low-risk febrile neutropenia in children-an implementation study in a tertiary paediatric hospital. Support Care Cancer. 2021; 29: 1609-1617.
48. Brands MR, Gouw SC, Beestrum M, et al. Patient-Centered Digital Health Records and Their Effects on Health Outcomes: Systematic Review. J Med Internet Res. 2022; 24: e43086.
49. May JE, Irelan PC, Boedeker K, et al. Systems-based hematology: highlighting successes and next steps. Blood Adv. 2020; 4: 4574-4583.
50. Tesi B, Boileau C, Boycott KM, et al. Precision medicine in rare diseases: What is next?. J Intern Med. 2023; 294: 397-412.
51. Sumner M, Ray W, Fiedler S, et al. A Mixed-Method Study of Practitioners' Perspectives on Issues Related to EHR Medication Reconciliation at a Health System. Qual Manag Health Care. 2019; 28: 84-95.
52. Marien S, Krug B, Spinewine A. Electronic tools to support medication reconciliation: a systematic review. J Am Med Inform Assoc. 2017; 24: 227-240.
53. Fraczkowski D, Matson J, Lopez KD. Nurse workarounds in the electronic health record: An integrative review. J Am Med Inform Assoc. 2020; 27: 1149-1165.
54. Mettler C, Daguzan A, Lagouanelle MC, et al. Expectation of patients and caregivers about patient education for immune thrombocytopenia. Rev Med Interne. 2021; 42: 3-10.
55. Grover S, Chaurasiya N, Chakrabarti S. Clinician Reasons for Stopping Clozapine: A Retrospective Cohort Study. J Clin Psychopharmacol. 2023; 43: 403-406.
56. Aguado JM, Cruz JJ, Virizuela JA, et al. Management of Infection and Febrile Neutropenia in Patients with Solid Cancer. Enferm Infecc Microbiol Clin. 2017; 35: 451-460.
57. Otto Mattsson T, Lindhart CL, Schöley J, et al. Patient self-testing of white blood cell count and differentiation: A study of feasibility and measurement performance in a population of Danish cancer patients. Eur J Cancer Care (Engl). 2020; 29: e13189.
58. Mak WC, Yin Ching SS. Effect of an education program on knowledge, self-care behavior and handwashing competence on prevention of febrile neutropenia among breast cancer patients receiving Doxorubicin and Cyclophosphamide in Chemotherapy Day Centre. Asia Pac J Oncol Nurs. 2015; 2: 276-288.
59. Huebner H, Wurmthaler LA, Goossens C, et al. A Digital Home-Based Health Care Center for Remote Monitoring of Side Effects During Breast Cancer Therapy: Prospective, Single-Arm, Monocentric Feasibility Study. JMIR Cancer. 2025; 11: e64083.

60. Takenaka S, Moro H, Shimizu U, et al. Preparing of Point-of-Care Reagents for Risk Assessment in the Elderly at Home by a Home-Visit Nurse and Verification of Their Analytical Accuracy. Diagnostics (Basel). 2023; 13: 2407.
61. Garbe E. Non-chemotherapy drug-induced agranulocytosis. Expert Opin Drug Saf. 2007; 6: 323-335.
62. He Y, Li J, Zheng J, et al. Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16 years at one Chinese center. J Endocrinol Invest. 2017; 40: 733-740.
63. Assimacopoulos A, Alam R, Arbo M, et al. A brief retrospective review of medical records comparing outcomes for inpatients treated via telehealth versus in-person protocols: is telehealth equally effective as in-person visits for treating neutropenic fever, bacterial pneumonia, and infected bacterial wounds?. Telemed J E Health. 2008; 14: 762-768.
64. Gallardo-Pizarro A, Peyrony O, Chumbita M, et al. Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning. Expert Rev Anti Infect Ther. 2024; 22: 179-187.
65. Mithoowani S, Cameron L, Crowther MA. Neutropenia. CMAJ. 2022; 194: E1689.
66. Medrano-Casique N, Tong HY, Borobia AM, et al. Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. Pediatr Hematol Oncol. 2016; 33: 441-456.
67. De Las Cuevas C, Sanz EJ, De Leon J. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety. Patient Prefer Adherence. 2024; 18: 2261-2280.
68. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020; 99: 2477-2482.
69. Njue L, Porret N, Schnegg-Kaufmann AS, et al. Isolated Severe Neutropenia in Adults, Evaluation of Underlying Causes and Outcomes, Real-World Data Collected over a 5-Year Period in a Tertiary Referral Hospital. Medicina (Kaunas). 2024; 60: 1576.
70. Wu S, Huang L, Chen J, et al. Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database. Front Pharmacol. 2025; 16: 1525307.